NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals announced that its board has authorized a stock repurchase plan on Thursday, August 10th 2017, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 13.3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's management believes its shares are undervalued.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.15. The specialty pharmaceutical company earned $59.30 million during the quarter, compared to analysts' expectations of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

4 brokers have issued 12 month target prices for Eagle Pharmaceuticals' shares. Their forecasts range from $52.00 to $80.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $62.50 in the next year. This suggests a possible upside of 35.2% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

News stories about EGRX stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next few days.

Some companies that are related to Eagle Pharmaceuticals include Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Arena Pharmaceuticals (ARNA), Endo International (ENDP), Akcea Therapeutics (AKCA), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Insmed (INSM), Endocyte (ECYT) and Supernus Pharmaceuticals (SUPN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), NVIDIA (NVDA), Horizon Pharma (HZNP), Radius Health (RDUS) and Clovis Oncology (CLVS).

Eagle Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.61%), Park West Asset Management LLC (7.04%), JW Asset Management LLC (2.85%), D. E. Shaw & Co. Inc. (1.91%), Millennium Management LLC (1.91%) and WINTON GROUP Ltd (1.59%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Scott Tarriff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rothschild & Co. Asset Management US Inc., New York State Common Retirement Fund, JW Asset Management LLC, Bank of New York Mellon Corp, Northern Trust Corp, Canada Pension Plan Investment Board and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Sander A Flaum and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Millennium Management LLC, WINTON GROUP Ltd, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Citigroup Inc., Chartwell Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $46.23.

Eagle Pharmaceuticals has a market capitalization of $689.43 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]